A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT)

PHASE2CompletedINTERVENTIONAL

Enrollment

300

Participants

Timeline

Start Date

Not specified

Study Completion Date

August 31, 1998

Conditions

Cytomegalovirus RetinitisHIV Infections

Interventions

DRUG

Sevirumab

Trial Locations (6)

New York Univ Med Ctr / SOCA, New York

Northwestern Univ / SOCA, Chicago

UCSF - San Francisco Gen Hosp, San Francisco

Johns Hopkins Hosp / SOCA, Baltimore

UCLA - Jules Stein Eye Institute / SOCA, Los Angeles

UCSD - Shiley Eye Ctr / SOCA, La Jolla

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00000836 - A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT) | Biotech Hunter | Biotech Hunter